美股市场个股详情
PEPG PepGen
- 13.950
- -0.250-1.76%
收盘价 05/06 16:00 (美东)
4.52亿总市值-4227市盈率TTM
14.640最高价13.640最低价4.35万股成交量14.230今开14.200昨收60.73万成交额0.27%换手率亏损市盈率(静)3239.04万总股本17.51052周最高4.17市净率2.22亿流通值3.72052周最低--股息TTM1588.10万流通股20.000历史最高--股息率TTM7.04%振幅3.720历史最低13.968平均价1股每手
PepGen股票讨论区
登录发表评论
$PepGen(PEPG.US$ PepGen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For PGN-EDO51 For The Treatment Of Duchenne Muscular Dystrophy
4
Mary Beth DeLena's addition to PepGen's executive team is viewed positively, her vast legal and compliance experience is anticipated to significantly contribute to PepGen's aim of providing next-gen oligonucleotide therapies for severe neuromuscular and neurological diseases.
$PepGen(PEPG.US$
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the first patient has been dosed in its CONNECT1-EDO51 Phase 2, open-label multiple ascending dose (MAD) clinical trial evaluating PGN-EDO51 for the ...
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the first patient has been dosed in its CONNECT1-EDO51 Phase 2, open-label multiple ascending dose (MAD) clinical trial evaluating PGN-EDO51 for the ...
1
$PepGen(PEPG.US$ PepGen Announced First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
Benzinga· 5 mins ago![]()
Benzinga· 5 mins ago
1
$PepGen(PEPG.US$ promising data from their 5mg/Kg dose level cohort, which is expected to be shared in mid-2024. This data suggests a high dystrophin expression, which is a strong indicator of PGN-EDO51’s effectiveness. In a head-to-head comparison with SRP-5051, PGN-EDO51 showed a 13-fold increase in exon skipping. Additionally, PepGen’s PGN-EDODM1 has shown promising early results, with significant correction of mis-splicing and myotonia after a single dose, and a tolerabili...
$PepGen(PEPG.US$ The FDA Has Lifted The Full Clinical Hold And Cleared PepGen's Investigational New Drug Application To Initiate The FREEDOM-DM1 Phase 1 Study Of PGN-EDODM1 For Myotonic Dystrophy Type 1![]()
1
3
2
ABOS PEPG TOPS AAPL DIS XPEV MNMD TSM QTRX
$Acumen Pharmaceuticals(ABOS.US$ $PepGen(PEPG.US$ $Top Ships(TOPS.US$ $苹果(AAPL.US$ $迪士尼(DIS.US$ $小鹏汽车(XPEV.US$ $Mind Medicine(MNMD.US$ $台积电(TSM.US$ $Quanterix(QTRX.US$
1
2
暂无评论
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
sendhelp : any tips on the "emotion" side of trading? I tend to panic sell when it dips thinking it will keep dropping but it ends up rising right after, like in $NuCana (NCNA.US)$ I brought it avg 0.83 and sold it for 0.71 when it dip down..
Trytosaveabit楼主 sendhelp: First PM and AM are hard to trade because you don’t get a true picture of interest/liquidity. Second use your indicators and volume to decide if it’s a actual dip or is it drop on low volume! Here is what I recommend indicator wise! 8 and 9 EMA on the 5, 10 and 15 minute charts after i am already in a ticker! But remember volatility and volume have to be used in tandem! That way if drops below your indicator it could just be a SL, or a bit of profit taking but will recover! I seen the drop you’re talking about and it was a low volume drop that didn’t bother me! Hope this helps?
sendhelp Trytosaveabit楼主: I see now, thanks a lot! Are you still positive with the ticker $NuCana (NCNA.US)$ ? and do you think I could possibly reenter maybe during market open?
Trytosaveabit楼主 sendhelp: I am still positive on it! I am actually looking to try to get back in below .80 to see what happens at 8:00 and then into market open! NFA JMO! GL